Zorbtive™ (somatropin for injection) is a recombinant human growth hormone which represents a significant advance in the treatment of short bowel syndrome (SBS).

In individual studies, growth hormone has been shown to enhance absorption of water, electrolytes and nutrients in the shortened bowel. As a result, patients prescribed Zorbtive™ may be able to reduce dependence on parenteral nutrition for the body's required fluids and nutrients and enjoy an improved quality of life.

Zorbtive™ is the only recombinant human growth hormone approved by the FDA for the treatment of SBS in patients receiving specialized nutritional support and it has Orphan Drug market exclusivity in the USA until 2010.

For information on Zorbtive™, US residents should visit www.emdserono.com